Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey
Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey
复制标题
DOI：
10.1007/s10147-011-0254-y
复制
发表时间：
2012-02-01
影响因子：
3.3
通讯作者：
Tamamoto, Tetsuro
中科院分区：
文献类型：
--
作者：
Nishimura, Yasumasa;Koike, Ryuta;Tamamoto, Tetsuro
为了确定放射治疗（RT）在日本食管癌的临床效果，我们对1999年至2003年期间接受确定性RT治疗的食管癌进行了一项基于放射学的调查。从9个主要机构收集了患者确定性RT的临床结果。仅纳入接受总剂量≥ 50戈伊的体能状态良好（PS 0-2）的患者。将患者分为三组：（A）I期，（B）可切除的II-III期，（C）不可切除的III-IVA期。A组为单纯放疗组或放化疗组。对于B和C组，仅包括接受CRT治疗的患者，总共有167例患者被纳入A组，239例患者被纳入B组，244例患者被纳入C组。A组约一半患者接受CRT治疗。中位总RT剂量范围为60至66戈伊。A组、B组和C组的5年总生存率中位数和范围分别为56%（48-83%）、29%（12-52%）和19%（0-31%）。注意到各机构的总体存活率差异很大。注意到B组和C组每年治疗的患者数量与5年总生存率之间存在显著相关性（均p < 0.05）。尽管I期食管癌的总生存率非常好，但在接受CRT治疗的II-IVA期肿瘤的机构中，生存率存在显著差异。
To determine the clinical results of radiotherapy (RT) for esophageal cancer in Japan.A questionnaire-based survey was conducted for esophageal cancer treated by definitive RT between 1999 and 2003. Clinical results of definitive RT for patients were collected from 9 major institutions. Only patients with good performance status (PS 0-2) who received a total dose of 50 Gy or more were included. Patients were classified into three groups: (A) stage I, (B) resectable stages II-III, (C) unresectable stages III-IVA. For group A, all patients treated by RT alone or chemo-radiotherapy (CRT) were included. For groups B and C, only those treated by CRT were included.In total, 167 patients were included in group A, 239 in group B, and 244 in group C. Approximately half of the patients in group A were treated by CRT. The median total RT dose ranged from 60 to 66 Gy. The median and range of the 5-year overall survival rates were 56% (48-83%) for group A, 29% (12-52%) for group B, and 19% (0-31%) for group C, respectively. A wide disparity in overall survival rates was noted among the institutions. A significant correlation between the number of patients treated per year and the 5-year overall survival rate was noted for groups B and C (both p < 0.05).Although the overall survival rates for stage I esophageal cancer were excellent, a significant disparity in survival rates was noted among the institutions for stage II-IVA tumors treated by CRT.